MLTX - Company ID 0001821586
The table below shows MoonLake Immunotherapeutics's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$66.29M | -$38.14M | -$14.95M | -$9.02M | -$14.19M | -$107.80K |
| Capital expenditure | $0.00 | $35.00K | $212.00K | $0.00 | $16.01K | - |
| Investing cash flow | $98.00K | $56.25M | -$28.80M | $19.65M | -$16.01K | - |
| Dividends paid | - | - | - | - |
MoonLake Immunotherapeutics reported operating cash flow of -$196.01M for fiscal year 2025. That is down 68.1% from -$116.59M in fiscal 2024. Over the 5 fiscal years shown, operating cash flow declined from -$611.07K (FY 2021) to -$196.01M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | $50.00 | $0.00 | - | - |
| Financing cash flow | $30.64M | $73.12M | $50.98M | $0.00 | $15.00M | -$58.06K |